Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2353
mi
from 98109
Albany, NY
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2281
mi
from 98109
Charlotte, NC
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1931
mi
from 98109
Lima, OH
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
367
mi
from 98109
Medford, OR
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
367
mi
from 98109
Medford, OR
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2373
mi
from 98109
Philadelphia, PA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2486
mi
from 98109
Providence, RI
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2486
mi
from 98109
Providence, RI
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2423
mi
from 98109
Charleston, SC
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1971
mi
from 98109
Nashville, TN
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1770
mi
from 98109
Austin, TX
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2351
mi
from 98109
Richmond, VA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
10
mi
from 98109
Mountlake Terrace, WA
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
2161
mi
from 98109
Morgantown, WV
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
2161
mi
from 98109
Morgantown, WV
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Clinical Trial Facility
1687
mi
from 98109
Milwaukee, WI
The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.
Early Access of TMC125 in Combination With Other Antiretrovirals in Treatment-experienced HIV-1 Infected Subjects With Limited Treatment Options.
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1687
mi
from 98109
Milwaukee, WI
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States
Status: Archived
University of Colorado at Denver and Health Sciences Center
1023
mi
from 98109
Denver, CO
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States
Status: Archived
Updated: 1/1/1970
University of Colorado at Denver and Health Sciences Center
1023
mi
from 98109
Denver, CO
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States
Status: Archived
AIDS Research Consortium of Atlanta
2178
mi
from 98109
Atlanta, GA
Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
An Open-Label Randomized Clinical Trial to Evaluate the Efficacy and Safety of Short Course Antiretroviral Therapy for Acute or Recent HIV-1 Infection in Zimbabwe and the United States
Status: Archived
Updated: 1/1/1970
AIDS Research Consortium of Atlanta
2178
mi
from 98109
Atlanta, GA
Assisting HIV-Infected Mothers in Disclosing Their Serostatus to Their Children
Maternal HIV: Intervention to Assist Disclosure to Children
Status: Archived
University of Southern California Women's and Children's Hospital
961
mi
from 98109
Los Angeles, CA
Assisting HIV-Infected Mothers in Disclosing Their Serostatus to Their Children
Maternal HIV: Intervention to Assist Disclosure to Children
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
961
mi
from 98109
Los Angeles, CA
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
Armodafinil Treatment for Fatigue in HIV+ Patients
Status: Archived
New York State Psychiatric Insitute
2400
mi
from 98109
New York, NY
Effectiveness of Armodafinil for Treating Fatigue in Adults With HIV/AIDS
Armodafinil Treatment for Fatigue in HIV+ Patients
Status: Archived
Updated: 1/1/1970
New York State Psychiatric Insitute
2400
mi
from 98109
New York, NY
IMARA, Adapting SiHLE for Detained African American Adolescent Females
IMARA, Adapting SiHLE for Detained African American Adolescent Females
Status: Archived
Metro Regional Youth Detention Center
2182
mi
from 98109
Atlanta, GA
IMARA, Adapting SiHLE for Detained African American Adolescent Females
IMARA, Adapting SiHLE for Detained African American Adolescent Females
Status: Archived
Updated: 1/1/1970
Metro Regional Youth Detention Center
2182
mi
from 98109
Atlanta, GA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
LAC+USC Medical Center, Rand Schrader Clini
962
mi
from 98109
Los Angeles, CA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
Updated: 1/1/1970
LAC+USC Medical Center, Rand Schrader Clini
962
mi
from 98109
Los Angeles, CA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
UC San Diego Medical Center
1063
mi
from 98109
San Diego, CA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
Updated: 1/1/1970
UC San Diego Medical Center
1063
mi
from 98109
San Diego, CA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
Harbor-UCLA Med Ctr
979
mi
from 98109
Torrance, CA
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
A Phase I Evaluation of the Safety and Biologic Activity of TXA127 in HIV-Infected Subjects With CD4+ T-Lymphocyte Counts Less Than 250 Per mm3 Who Have Responded to HAART
Status: Archived
Updated: 1/1/1970
Harbor-UCLA Med Ctr
979
mi
from 98109
Torrance, CA
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
Status: Archived
Yale University School of Medicine
2432
mi
from 98109
New Haven, CT
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
2432
mi
from 98109
New Haven, CT
Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
Status: Archived
Thomas Street Clinic
1888
mi
from 98109
Houston, TX
Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients
Status: Archived
Updated: 1/1/1970
Thomas Street Clinic
1888
mi
from 98109
Houston, TX
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Status: Archived
Staten Island University Hospital
2402
mi
from 98109
Staten Island, NY
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?
Status: Archived
Updated: 1/1/1970
Staten Island University Hospital
2402
mi
from 98109
Staten Island, NY
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
Status: Archived
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
University of Alabama - Burmingham
2072
mi
from 98109
Birmingham, AL
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
2072
mi
from 98109
Birmingham, AL
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Harbor-UCLA Med Ctr
979
mi
from 98109
Torrance, CA
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Updated: 1/1/1970
Harbor-UCLA Med Ctr
979
mi
from 98109
Torrance, CA
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
University of Illinois College of Medicine
1731
mi
from 98109
Chicago, IL
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Updated: 1/1/1970
University of Illinois College of Medicine
1731
mi
from 98109
Chicago, IL
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
SNBL Clinical Pharmacology Center
2327
mi
from 98109
Baltimore, MD
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Updated: 1/1/1970
SNBL Clinical Pharmacology Center
2327
mi
from 98109
Baltimore, MD
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Albert Einstein College of Medicine
2405
mi
from 98109
Bronx, NY
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
A Double-blind, Randomized, Placebo-controlled Phase I/II Trial to Evaluate the Safety of Dapivirine Gel, 0.05%, 2.5g and Dapivirine Gel 2759, 0.05%, 2.5g Formulations as Compared to the Vaginal HEC-based Universal Placebo Gel, 2.5g in Healthy, HIV-negative Women.
Status: Archived
Updated: 1/1/1970
Albert Einstein College of Medicine
2405
mi
from 98109
Bronx, NY
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Alabama Therapeutics CRS
2072
mi
from 98109
Birmingham, AL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Alabama Therapeutics CRS
2072
mi
from 98109
Birmingham, AL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Miller Children's Hospital Long Beach
979
mi
from 98109
Long Beach, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Miller Children's Hospital Long Beach
979
mi
from 98109
Long Beach, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Los Angeles County-USC Medical Center
962
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
962
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
960
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
UCLA Center for Clinical AIDS Research and Education (CARE) Clinic
960
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Stanford CRS
707
mi
from 98109
Palo Alto, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Stanford CRS
707
mi
from 98109
Palo Alto, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
University of Southern California Women's and Children's Hospital
961
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
961
mi
from 98109
Los Angeles, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Ucsf Aids Crs
683
mi
from 98109
San Francisco, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Ucsf Aids Crs
683
mi
from 98109
San Francisco, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Harbor UCLA Medical Center
976
mi
from 98109
Torrance, CA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
University of Colorado, Boulder
989
mi
from 98109
Boulder, CO
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
989
mi
from 98109
Boulder, CO
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Denver Public Health CRS
1019
mi
from 98109
Denver, CO
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Denver Public Health CRS
1019
mi
from 98109
Denver, CO
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Howard University Hospital
2322
mi
from 98109
Washington,
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Howard University Hospital
2322
mi
from 98109
Washington,
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Georgetown Univ Med Ctr
2320
mi
from 98109
Washington,
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
2320
mi
from 98109
Washington,
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
University of Miami Hospital
2730
mi
from 98109
Miami, FL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Ponce de Leon Center
2178
mi
from 98109
Atlanta, GA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Ponce de Leon Center
2178
mi
from 98109
Atlanta, GA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Northwestern University
1733
mi
from 98109
Chicago, IL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Northwestern University
1733
mi
from 98109
Chicago, IL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
1730
mi
from 98109
Chicago, IL
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Johns Hopkins Hosp
2329
mi
from 98109
Baltimore, MD
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
2329
mi
from 98109
Baltimore, MD
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
IHV Baltimore Treatment CRS
2327
mi
from 98109
Baltimore, MD
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
IHV Baltimore Treatment CRS
2327
mi
from 98109
Baltimore, MD
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Boston Med Center
2485
mi
from 98109
Boston, MA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Boston Med Center
2485
mi
from 98109
Boston, MA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Brigham & Women's Hospital Women's Health Center
2481
mi
from 98109
Chestnut Hill, MA
Comparative Study of Three NNRTI-Sparing HAART Regimens
A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment)
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
2481
mi
from 98109
Chestnut Hill, MA